EORTC-EANO-ESMO Trends in Central Nervous System Malignancies Conference 2013

Oncology Meeting Resources

22 Mar - 23 Mar, Prague, Czech Republic

On this page, PDF versions of presentations given at the EORTC-EANO-ESMO Trends in Central Nervous System Malignancies Conference 2013 are available to ESMO members according to the presenters' agreement to release them. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Search Meeting Resources by Keyword

 

Useful link

Presenter Presentation title Session title
A. von Deimling 1 - IDH1: from mutation to marker to target? Basic Developments in Glioma
J. Seoane 2 - Transforming growth factor beta: 30 years later Basic Developments in Glioma
M. Hegi 3 - IDH, MGMT or genome wide methylation? Diagnosis and Prognosis
J. Pallud 4 - MR imaging follow-up for diffuse low-grade glioma: what can we learn? Diagnosis and Prognosis
O. Chinot 5 - Bevacizumab and glioma: first data from AVAGLIO Management of Glioblastoma
J. Tonn 6 - Surgery vs radiosurgery in vestibular schwannoma - Surgery Controversies (I)
P. Hanssens 7 - Surgery vs radiosurgery in vestibular schwannoma - Radiosurgery Controversies (I)
M. van den Bent 8 - Radiotherapy and adjuvant chemotherapy the new standard of care for 1p/19q co-deleted anaplastic oligodendroglioma? Management of Grade 2 and 3 Glioma
W. Wick 9 - PCV or Temozolomide: What is the Regimen of Choice? Management of Grade 2 and 3 Glioma
R. Soffietti 10 - Are molecular markers and advanced neuro-imaging useful to predict and monitor response to treatments in grade 2 gliomas? Management of Grade 2 and 3 Glioma
M. Weller 11 - Targeting the EGFRvIII receptor: new promise for immunotherapy? Novel Clinical Trials
D. Frappaz 12 - Targeting the hedgehog pathway in medulloblastoma Novel Clinical Trials
U. Schlegel 13 - Whole brain radiotherapy in primary CNS lymphomas Controversies (II)
R. Kortmann 14 - Intracranial germinoma Rare Tumours
B. Baumert 15 - Reirradiation in gliomas: in favour Controversies (III)